Your browser doesn't support javascript.
loading
PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care.
Kolber, Michael R; Klarenbach, Scott; Cauchon, Michel; Cotterill, Mike; Regier, Loren; Marceau, Raelene D; Duggan, Norah; Whitley, Rebecca; Halme, Alex S; Poshtar, Tanis; Allan, G Michael; Korownyk, Christina S; Ton, Joey; Froentjes, Liesbeth; Moe, Samantha S; Perry, Danielle; Thomas, Betsy S; McCormack, James P; Falk, Jamie; Dugré, Nicolas; Garrison, Scott R; Kirkwood, Jessica E M; Young, Jennifer; Braschi, Émélie; Paige, Allison; Potter, Jen; Weresch, Justin; Lindblad, Adrienne J.
Afiliación
  • Kolber MR; Professor in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Klarenbach S; Nephrologist and Professor in the Department of Medicine and Dentistry at the University of Alberta.
  • Cauchon M; Professor in the Département de médecine familiale et d'urgence at Université Laval in Québec City, Que.
  • Cotterill M; Assistant Professor in the Division of Clinical Sciences at the Northern Ontario School of Medicine University based in Wawa.
  • Regier L; Consulting Editor for the RxFiles Academic Detailing Program at the University of Saskatchewan in Saskatoon.
  • Marceau RD; Assistant Professor in the School of Nursing at the University of Northern British Columbia in Prince George.
  • Duggan N; Associate Professor in the Department of Family Medicine at Memorial University of Newfoundland in St John's.
  • Whitley R; Assistant Professor in the Department of Family Medicine at the University of Manitoba in Winnipeg.
  • Halme AS; Internist-geriatrician at CISSS Montérégie-est (Hôpital Pierre-Boucher) and CISSS de la Gaspésie in Quebec.
  • Poshtar T; Patient in Edmonton.
  • Allan GM; Director of Programs and Practice Support at the College of Family Physicians of Canada (CFPC).
  • Korownyk CS; Professor in the Department of Family Medicine at the University of Alberta.
  • Ton J; Program Manager of Programs and Practice Support at the CFPC.
  • Froentjes L; Research assistant in the Department of Family Medicine at the University of Alberta.
  • Moe SS; Clinical Evidence Expert for the CFPC.
  • Perry D; Clinical Evidence Expert for the CFPC and Assistant Adjunct Professor in the Department of Family Medicine at the University of Alberta.
  • Thomas BS; Clinical Evidence Expert for the CFPC and Assistant Adjunct Professor in the Department of Family Medicine at the University of Alberta.
  • McCormack JP; Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia in Vancouver.
  • Falk J; Pharmacist and Associate Professor in the College of Pharmacy at the University of Manitoba.
  • Dugré N; Pharmacist at the CIUSSS du Nord-de-l'Île-de-Montréal and Clinical Associate Professor in the Faculty of Pharmacy at the University of Montréal in Quebec.
  • Garrison SR; Professor in the Department of Family Medicine at the University of Alberta.
  • Kirkwood JEM; Family physician and Assistant Professor in the Department of Family Medicine at the University of Alberta.
  • Young J; Family physician practising in Collingwood, Ont.
  • Braschi É; Hospitalist at the Élisabeth Bruyère Hospital in Ottawa, Ont, and a physician adviser at the CFPC.
  • Paige A; Assistant Professor in the Department of Family Medicine at the University of Manitoba.
  • Potter J; Assistant Professor in the Department of Family Medicine at the University of Manitoba.
  • Weresch J; Assistant Professor in the Department of Family Medicine at McMaster University in Hamilton, Ont.
  • Lindblad AJ; Clinical Evidence Expert Lead for the CFPC and Associate Clinical Professor in the Department of Family Medicine at the University of Alberta.
Can Fam Physician ; 69(10): 675-686, 2023 10.
Article en En | MEDLINE | ID: mdl-37833089
ABSTRACT

OBJECTIVE:

To update the 2015 clinical practice guideline and provide a simplified approach to lipid management in the prevention of cardiovascular disease (CVD) for primary care.

METHODS:

Following the Institute of Medicine's Clinical Practice Guidelines We Can Trust, a multidisciplinary, pan-Canadian guideline panel was formed. This panel was represented by primary care providers, free from conflicts of interest with industry, and included the patient perspective. A separate scientific evidence team performed evidence reviews on statins, ezetimibe, proprotein convertase subtilisin-kexin type 9 inhibitors, fibrates, bile acid sequestrants, niacin, and omega-3 supplements (docosahexaenoic acid with eicosapentaenoic acid [EPA] or EPA ethyl ester alone [icosapent]), as well as on 11 supplemental questions. Recommendations were finalized by the guideline panel through use of the Grading of Recommendations Assessment, Development and Evaluation methodology.

RECOMMENDATIONS:

All recommendations are presented in a patient-centred manner designed with the needs of family physicians and other primary care providers in mind. Many recommendations are similar to those published in 2015. Statins remain first-line therapy for both primary and secondary CVD prevention, and the Mediterranean diet and physical activity are recommended to reduce cardiovascular risk (primary and secondary prevention). The guideline panel recommended against using lipoprotein a, apolipoprotein B, or coronary artery calcium levels when assessing cardiovascular risk, and recommended against targeting specific lipid levels. The team also reviewed new evidence pertaining to omega-3 fatty acids (including EPA ethyl ester [icosapent]) and proprotein convertase subtilisin-kexin type 9 inhibitors, and outlined when to engage in informed shared decision making with patients on interventions to lower cardiovascular risk.

CONCLUSION:

These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Anticolesterolemiantes Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Can Fam Physician Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Anticolesterolemiantes Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Can Fam Physician Año: 2023 Tipo del documento: Article